Experience

Lexeo Therapeutics Announces $100 Million IPO

November 3, 2023

Cooley advised Lexeo Therapeutics, a clinical-stage gene therapy company advancing gene therapy candidates for genetically defined cardiovascular diseases and a genetically defined subgroup of Alzheimer’s disease, on its approximately $100 million initial public offering.

Read more

Related contacts

Eric Blanchard
Partner, Boston
Peter Byrne
Partner, New York
Div Gupta
Partner, New York
Ivor Elrifi
Partner, New York
Matthew Pavao
Partner, Boston
Xander Lee
Partner, Los Angeles Santa Monica
Barbara Mirza
Partner, Los Angeles Santa Monica
Aaron Pomeroy
Partner, Colorado
Phil Mitchell
Partner, New York
Mark Ballantyne
Partner, Reston
Francis Wheeler
Partner, Colorado
Natasha Leskovsek
Of Counsel, Washington, DC
Stephanie Parker Palmer
Special Counsel, Reston
Joseph Lockinger
Special Counsel, Washington, DC
Christophe Beauduin
Special Counsel, New York
Randy Sabett
Special Counsel, Washington, DC
Jennifer Shanley
Special Counsel, New York
Reid Hooper
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Dayne Brown
Associate, New York
Ibe Alozie
Associate, Washington, DC
Christopher Nickas
Associate, New York
DeVon Barnett
Associate, Washington, DC
Carly Robinson
Associate, Reston
Calvin Lee
Associate, New York
Jayne M. Munger
Associate, New York
Megan Drill
Associate, San Diego
Erika Freeman
Associate, New York
Mor Agam
Associate, New York
Wyatt Kernell
Associate, New York
Wyatt Kernell
Associate, New York
Alexander Fullman
Associate, New York
Jason Minio
Paralegal Specialist, Boston
Andrew Henderson
Patent Agent, Seattle

Related Practices & Industries

Cooley Advises on MindMed’s Successful Proxy Contest

June 21, 2023

Cooley advised MindMed, a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, on its successful proxy contest against FCM MM Holdings.

Read more

Related contacts

Bill Roegge
Partner, New York
Christian Plaza
Partner, Reston
Mark Ballantyne
Partner, Reston
Kenneth Guernsey
Senior Counsel , San Francisco
Sarah Lightdale
Partner, New York
Kaitland Kennelly
Partner, New York
Megan Arthur Schilling
Partner, San Diego
Aric Wu
Partner, New York
Dayne Brown
Associate, New York
Amanda L. Liverzani
Associate, New York
Andrew Mettry
Associate, Chicago
Natasha Patel
Associate, New York
Dionne A. Thomas
Associate, San Diego
Charlotte Yin
Associate, New York

Related Practices & Industries

Exscientia – $510.4 Million IPO

October 6, 2021

Cooley advised Exscientia, an AI-driven pharmatech company based in Oxford, United Kingdom, on its $510.4 million initial public offering, including concurrent private placements to SoftBank and the Bill & Melinda Gates Foundation. Partners David Boles, Claire Keast-Butler, Div Gupta and Marc Recht led the Cooley team advising Exscientia.

Read more

Related contacts

David Boles
Partner, London
Claire Keast-Butler
Partner, London
Div Gupta
Partner, New York
Marc Recht
Partner, Boston
David Wilson
Partner, London
Chris Stack
Partner, London
Dayne Brown
Associate, New York
Meg Begur
Associate, Palo Alto
Nicola Squire
Partner, London
Jack Jones
Associate, London
Charlotte Irvine
Associate, London
Tom Goodman
Partner, London
Paula Holland
Partner, London
Aaron Pomeroy
Partner, Colorado
Calvin Lee
Associate, New York
Ivor Elrifi
Partner, New York
Courtney Thorne
Partner, Boston

Related Practices & Industries

VectivBio – $147 Million IPO

June 7, 2021

Cooley advised Vectiv Bio Holding on its $146.6 million initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters’ option to purchase additional shares. VectivBio, whose securities now trade on the Nasdaq Global Market under the symbol “VECT,” is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Partners Div Gupta, Ryan Sansom and Brandon Fenn led the Cooley team.

Related contacts

Dayne Brown
Associate, New York

Gamida Cell Closes $75 Million Financing With Highbridge Capital Management

March 2, 2021

Cooley advised Gamida Cell on its $75 million financing with Highbridge Capital Management. Partner Mischi a Marca led the Cooley team advising Gamida Cell, a cell therapy company working to develop cures for blood cancers and hematologic diseases.

Related contacts

Patrick Flanagan
Partner, New York
Xander Lee
Partner, Los Angeles Santa Monica
Daniel I. Goldberg
Partner, New York
Timothy Nguyen
Special Counsel, San Francisco
Dayne Brown
Associate, New York
Patrick Sharma
Associate, Los Angeles Santa Monica

Related Practices & Industries

View more

Admissions & credentials

New York